[The metabolic syndrome and type-2 diabetes mellitus as conditions predisposing for malignant tumors].
Recently more and more evidences have emerged about the oncogenic effect of type 2 diabetes and metabolic syndrome. Among these evidences epidemiological data are in first line. There is a causal relationship according to gender, ethnicity and geographic situation between different tumors and type 2 diabetes/metabolic syndrome as well. Supposed pathomechanisms are obesity, cytokines, secreted excessively in adipose tissue, permanent and postprandial hyperglycemia, hyperinsulinism and insulin resistance, other growth factors, like proinsulin, insulin like growth factor-1, reactive oxygen species, angiogenesis, inflammation, and the multiple effects of inflammatory cytokines. It proved to be evident that both peroxisome-proliferator-activated receptors and the regulatory ubiquitin proteasome system have significant role in insulin sensitivity and in co-ordinating cell proliferation and angiogenesis. These mechanisms in metabolic syndrome are risk factors towards atherosclerosis and cancer diseases as well. This newly emerged knowledge may open new pathways in treating and preventing the above-mentioned pathologic processes.
Halmos
Tamás
T
Mazsihisz Szeretetkórház Diabéteszambulancia Budapest Amerikai út 53-55. 1145. fishwash@t-online.hu
Suba
Ilona
I
D052242:Adiponectin / Q000009:adverse effects / Q000378:metabolism; D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D049109:Cell Proliferation; D016207:Cytokines / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000453:epidemiology / Q000378:metabolism*; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000378:metabolism; D006946:Hyperinsulinism / Q000150:complications / Q000378:metabolism; D007249:Inflammation / Q000150:complications / Q000378:metabolism; D007333:Insulin Resistance; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000378:metabolism; D020738:Leptin / Q000009:adverse effects / Q000378:metabolism; D024821:Metabolic Syndrome / Q000150:complications* / Q000453:epidemiology / Q000378:metabolism*; D009369:Neoplasms / Q000098:blood supply / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism* / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000150:complications / Q000378:metabolism; D009765:Obesity / Q000150:complications / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000009:adverse effects; D012307:Risk Factors; D014452:Ubiquitins / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D052242:Adiponectin; D016207:Cytokines; D020738:Leptin; D047492:Peroxisome Proliferator-Activated Receptors; D017382:Reactive Oxygen Species; D014452:Ubiquitins; D042461:Vascular Endothelial Growth Factor A; D007334:Insulin-Like Growth Factor I